Scynexis (SCYX) Given News Sentiment Rating of 0.14

News coverage about Scynexis (NASDAQ:SCYX) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Scynexis earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2722611629811 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

SCYX stock traded up $0.02 during mid-day trading on Monday, reaching $1.30. 141,057 shares of the company traded hands, compared to its average volume of 380,793. The company has a current ratio of 4.43, a quick ratio of 4.43 and a debt-to-equity ratio of 0.48. Scynexis has a fifty-two week low of $1.23 and a fifty-two week high of $2.93.

Scynexis (NASDAQ:SCYX) last released its quarterly earnings results on Tuesday, March 13th. The company reported ($0.27) earnings per share (EPS) for the quarter. The company had revenue of $0.06 million for the quarter. Scynexis had a negative net margin of 10,383.59% and a negative return on equity of 85.99%.

In related news, CEO Marco Taglietti purchased 100,000 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was acquired at an average price of $1.69 per share, for a total transaction of $169,000.00. Following the purchase, the chief executive officer now owns 404,000 shares of the company’s stock, valued at $682,760. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have acquired a total of 141,500 shares of company stock valued at $237,155 in the last quarter. Company insiders own 4.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Scynexis (SCYX) Given News Sentiment Rating of 0.14” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3343785/scynexis-scyx-given-news-sentiment-rating-of-0-14.html.

About Scynexis

SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.

Insider Buying and Selling by Quarter for Scynexis (NASDAQ:SCYX)

Receive News & Ratings for Scynexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scynexis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Matson  vs. The Competition Head to Head Analysis
Matson vs. The Competition Head to Head Analysis
Dollar General  vs. The Competition Head to Head Review
Dollar General vs. The Competition Head to Head Review
Comparing OneMain  and Nelnet
Comparing OneMain and Nelnet
Contrasting Aegion  and Preformed Line Products
Contrasting Aegion and Preformed Line Products
$0.95 Earnings Per Share Expected for Winnebago Industries  This Quarter
$0.95 Earnings Per Share Expected for Winnebago Industries This Quarter
Urstadt Biddle Properties Inc.  Expected to Announce Quarterly Sales of $32.66 Million
Urstadt Biddle Properties Inc. Expected to Announce Quarterly Sales of $32.66 Million


Leave a Reply

© 2006-2018 Ticker Report. Google+.